{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T04:30:35Z","timestamp":1786595435092,"version":"build-2736575974"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pregnancy-associated breast cancer (PABC) is increasing globally and often presents at advanced stages with aggressive features, requiring chemotherapy that balances maternal efficacy and fetal safety. Although multidisciplinary team (MDT) management is recommended, real-world pharmacotherapy data, especially involving clinical pharmacists in Asian populations, are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to describe the clinical characteristics, chemotherapy regimens, premedication strategies, and maternal-fetal outcomes of PABC managed within an MDT framework, offering a clinical pharmacy perspective on medication management and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, single-center, cross-sectional study included patients diagnosed with PABC between January 2019 and December 2025 who received chemotherapy with clinical pharmacist involvement. Demographic characteristics, pathological findings, chemotherapy regimens, premedication protocols, adverse reactions, and maternal-fetal outcomes were extracted from the electronic medical record system by two independent investigators, with discrepancies resolved through consensus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 28 patients were included. The median age at diagnosis was 32.41 \u00b1 3.80 years. The majority of patients (64.29%) were diagnosed during the second trimester, and Stage II was the most common pathological stage (39.29%). Under the multidisciplinary model, the predominant pregnancy chemotherapy was anthracycline, cyclophosphamide, and docetaxel (EC-T), administered to 35.71% of patients. Regimen selection and premedication were routinely optimized. Adverse events managed through pharmacist-involved monitoring included leukopenia (7.14%) and severe myelosuppression (7.14%). Pharmacists also provided fetal safety counseling, growth guidance, and parental reassurance on long-term offspring outcomes, embedding pharmaceutical expertise into multidisciplinary care. Regarding maternal and fetal outcomes, 79.31% of patients delivered by cesarean section, 53.57% had full-term deliveries, and the mean neonatal birth weight was 2730 \u00b1 497\u00a0g. Low birth weight occurred in 28.57% of newborns, and 17.86% required admission to the Neonatal Intensive Care Unit (NICU).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides real-world evidence for the multidisciplinary management of PABC. In this small sample, second- and third-trimester chemotherapy appeared to be associated with acceptable maternal-fetal outcomes. Integration of clinical pharmacists into the MDT model facilitated evidence-based regimen design, individualized premedication strategies, and proactive adverse event monitoring. These preliminary findings support the feasibility of pharmacist-involved MDT care in PABC, though validation in larger prospective studies with long-term offspring follow-up is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1918932","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T04:23:35Z","timestamp":1786595015000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multidisciplinary management of pregnancy-associated breast cancer: a clinical pharmacy perspective on chemotherapy and perinatal outcomes"],"prefix":"10.3389","volume":"16","author":[{"given":"Haoran","family":"Liu","sequence":"first","affiliation":[{"name":"Obstetrics & Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[{"name":"Obstetrics & Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Deng","sequence":"additional","affiliation":[{"name":"Obstetrics & Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianli","family":"Wang","sequence":"additional","affiliation":[{"name":"Obstetrics & Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Obstetrics & Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1186\/s12885-025-14091-2","article-title":"A systematic review and meta-analysis of pregnancy-associated breast cancer incidence rate","volume":"25","author":"Akhlaqi","year":"2025","journal-title":"BMC Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000366436","article-title":"Pregnancy-associated breast cancer: clinicopathological characteristics of 20 cases with a focus on identifiable causes of diagnostic delay","volume":"9","author":"Basaran","year":"2014","journal-title":"Breast Care (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1839","article-title":"Pregnancy-associated breast cancer and metastasis","volume":"6","author":"Schedin","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-21-0206","article-title":"Pregnancy-associated breast cancer: the influence of gestational age","volume":"29","author":"Suelmann","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/ajco.13528","article-title":"Clinicopathological features and prognosis of patients with pregnancy-associated breast cancer: a matched case control study","volume":"17","author":"Zhang","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-025-07684-9","article-title":"Biology, care, and outcomes of gestational breast cancers: a review","volume":"211","author":"Duggirala","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.14811","article-title":"Long-term outcomes of children after prenatal exposure to maternal cancer and its treatment","volume":"103","author":"Huis In 't Veld","year":"2024","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B8","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2026\n          \n          \n          \n          2026"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002160","article-title":"Pregnancy-associated changes in pharmacokinetics: A systematic review","volume":"13","author":"Pariente","year":"2016","journal-title":"PloS Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S194768","article-title":"Pyrotinib treatment on HER2-positive gastric cancer cells promotes the released exosomes to enhance endothelial cell progression, which can be counteracted by apatinib","volume":"12","author":"Gao","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B11","first-page":"i","article-title":"NTP monograph: developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy","year":"2013","journal-title":"NTP Monogr"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10995-008-0348-y","article-title":"The association between major birth defects and preterm birth","volume":"13","author":"Honein","year":"2009","journal-title":"Matern Child Health J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.18270","article-title":"Pregnancy and breast cancer: green-top guideline no. 12","volume":"132","author":"Armstrong","year":"2025","journal-title":"BJOG"},{"key":"B14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.breast.2021.02.005","article-title":"Pregnancy associated breast cancer (PABC): Report from a gestational cancer registry from a tertiary cancer care centre, India","volume":"56","author":"Bajpai","year":"2021","journal-title":"Breast"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35619","article-title":"Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy","volume":"131","author":"Johnson","year":"2025","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(04)01466-4","article-title":"Use of chemotherapy during human pregnancy","volume":"5","author":"Cardonick","year":"2004","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ygyno.2010.08.019","article-title":"Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model","volume":"119","author":"Van Calsteren","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061238","article-title":"Cancer during pregnancy: A review of preclinical and clinical transplacental transfer of anticancer agents","volume":"13","author":"Benoit","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B19","article-title":"Passage transplacentaire de l'\u00e9pirubicine [Transplacental passage of epirubicin","volume":"24","author":"Gaillard","year":"1995","journal-title":"J Gynecol Obstet Biol Reprod (Paris)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181fb18c8","article-title":"Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model","volume":"20","author":"Calsteren","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.2024320","article-title":"Pregnancy-associated breast cancer: Management of the mother, fetus and tumour","volume":"54","author":"Tan","year":"2025","journal-title":"Ann Acad Med Singap"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30059-7","article-title":"Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients","volume":"19","author":"de Haan","year":"2019","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3310\/nihropenres.13652.2","article-title":"The UK Breast Cancer in Pregnancy (UKBCiP) Study. Incidence, diagnosis, management and short-term outcomes of breast cancer first diagnosed during pregnancy in the United Kingdom: A population-based descriptive study","volume":"4","author":"Hardy","year":"202","journal-title":"NIHR Open Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/1471-0528.17739","article-title":"The management of nausea and vomiting in pregnancy and hyperemesis gravidarum (Green-top guideline no. 69)","volume":"13","author":"Nelson-Piercy","year":"2024","journal-title":"BJOG"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13030132","article-title":"Hyperemesis in pregnancy: complications and treatment","volume":"13","author":"Gerede","year":"2025","journal-title":"Med Sci (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2014.10.017","article-title":"Use of ondansetron during pregnancy and congenital malformations in the infant","volume":"50","author":"Danielsson","year":"2014","journal-title":"Reprod Toxicol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/bdra.22865","article-title":"Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects","volume":"94","author":"Anderka","year":"2012","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.951072","article-title":"Risk of abnormal pregnancy outcomes after using ondansetron during pregnancy: A systematic review and meta-analysis","volume":"13","author":"Cao","year":"2022","journal-title":"Front Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000242156.15757.70","article-title":"Pulsed steroid therapy is an effective treatment for intractable hyperemesis gravidarum","volume":"34","author":"Bondok","year":"2006","journal-title":"Crit Care Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2024.05.012","article-title":"Optimization of the betamethasone and dexamethasone dosing regimen during pregnancy: a combined placenta perfusion and pregnancy physiologically based pharmacokinetic modeling approach","volume":"232","author":"Van Der Heijden","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2174\/1381612053507873","article-title":"Synthetic glucocorticoids: antenatal administration and long-term implications","volume":"11","author":"Sloboda","year":"2005","journal-title":"Curr Pharm Des"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241232692","article-title":"Comparative study of dexamethasone premedication regimens with docetaxel chemotherapy in early HER-2 positive breast cancer: A safety net hospital experience","volume":"31","author":"Hager","year":"2025","journal-title":"J Oncol Pharm Pract"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061691","article-title":"Phase 1 study to evaluate the safety of reducing the prophylactic dose of dexamethasone around docetaxel infusion in patients with prostate and breast cancer","volume":"15","author":"Lugtenberg","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B35","article-title":"Pretreatment with different doses of dexamethasone in the prevention of docetaxel-induced hypersensitivity","volume":"30","author":"Zhang","year":"2017","journal-title":"Pak J Pharm Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.14555","article-title":"Risk of obstetric and perinatal complications in women presenting with breast cancer during pregnancy and the first year postpartum in Sweden 1973-2017: A population-based matched study","volume":"103","author":"Lundberg","year":"2024","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70261-9","article-title":"Treatment of breast cancer during pregnancy: an observational study","volume":"13","author":"Loibl","year":"2012","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/pd.1557","article-title":"Prenatal sonographic diagnosis of congenital perineal skin tag: case report and review of the literature","volume":"26","author":"Bord","year":"2006","journal-title":"Prenat Diagn"},{"key":"B39","unstructured":"Open Vigil FDA - an Openfda API Based AERS Data Search Engine Pharmacovigilance Tool Made by the Openvigil Project\n          \n          \n          \n          2011"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/14767058.2022.2128645","article-title":"Impact of chemotherapy during pregnancy on fetal growth","volume":"35","author":"Maggen","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B41","unstructured":"Actions From Peer Review of the Draft NTP Monograph on Developmental Effects and Pregnancy Outcomes Associated With Cancer Chemotherapy Use During Pregnancy. October 1-2, 2012"},{"key":"B42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12885-023-11704-6","article-title":"Obstetric and neonatal outcomes following taxane use during pregnancy: a systematic review","volume":"24","author":"Aranda-Gutierrez","year":"2024","journal-title":"BMC Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70363-1","article-title":"Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study","volume":"13","author":"Amant","year":"2012","journal-title":"Lancet Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/ipd.12801","article-title":"Paediatric dental outcomes among children exposed to chemotherapy in utero","volume":"32","author":"Iyer","year":"2022","journal-title":"Int J Paediatr Dent"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1918932\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T04:23:37Z","timestamp":1786595017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1918932\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":44,"alternative-id":["10.3389\/fonc.2026.1918932"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1918932","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1918932"}}